Zacks: Brokerages Anticipate Charles River Laboratories Intl. Inc (CRL) Will Announce Quarterly Sales of $476.73 Million

Equities analysts forecast that Charles River Laboratories Intl. Inc (NYSE:CRL) will announce $476.73 million in sales for the current quarter, Zacks reports. Seven analysts have provided estimates for Charles River Laboratories Intl.’s earnings, with the lowest sales estimate coming in at $468.42 million and the highest estimate coming in at $486.00 million. Charles River Laboratories Intl. posted sales of $466.79 million during the same quarter last year, which would indicate a positive year over year growth rate of 2.1%. The company is scheduled to report its next quarterly earnings results before the market opens on Tuesday, February 13th.

According to Zacks, analysts expect that Charles River Laboratories Intl. will report full-year sales of $476.73 million for the current financial year, with estimates ranging from $1.85 billion to $1.87 billion. For the next fiscal year, analysts expect that the company will report sales of $1.99 billion per share, with estimates ranging from $1.97 billion to $2.03 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The company had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. During the same period in the previous year, the firm earned $1.18 EPS. The firm’s revenue was up 9.0% compared to the same quarter last year.

A number of research firms recently commented on CRL. Robert W. Baird set a $117.00 price target on Charles River Laboratories Intl. and gave the stock a “buy” rating in a report on Monday, November 13th. Zacks Investment Research raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a report on Tuesday, October 24th. Evercore ISI began coverage on Charles River Laboratories Intl. in a report on Thursday, January 18th. They issued an “in-line” rating and a $117.00 price target on the stock. SunTrust Banks cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating and boosted their price target for the stock from $107.89 to $111.00 in a report on Monday, January 22nd. They noted that the move was a valuation call. Finally, Bank of America lowered their price target on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, November 10th. Eight investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $112.58.

In other Charles River Laboratories Intl. news, Director Online Communications Bdirect sold 131,000 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $0.29, for a total value of $37,990.00. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. In the last ninety days, insiders sold 1,195,673 shares of company stock worth $2,914,046. Corporate insiders own 2.20% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. YorkBridge Wealth Partners LLC increased its stake in Charles River Laboratories Intl. by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after acquiring an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Charles River Laboratories Intl. by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after acquiring an additional 548 shares during the last quarter. Advisor Group Inc. increased its stake in Charles River Laboratories Intl. by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after acquiring an additional 945 shares during the last quarter. Zions Bancorporation bought a new stake in Charles River Laboratories Intl. in the 3rd quarter worth approximately $212,000. Finally, Koch Industries Inc. bought a new stake in Charles River Laboratories Intl. in the 2nd quarter worth approximately $240,000. 97.47% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories Intl. (CRL) opened at $100.83 on Wednesday. The company has a quick ratio of 1.62, a current ratio of 1.88 and a debt-to-equity ratio of 1.13. Charles River Laboratories Intl. has a twelve month low of $81.36 and a twelve month high of $119.05. The company has a market capitalization of $4,780.00, a P/E ratio of 24.65, a P/E/G ratio of 1.51 and a beta of 0.74.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/07/zacks-brokerages-anticipate-charles-river-laboratories-intl-inc-crl-will-announce-quarterly-sales-of-476-73-million.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply